Hints and tips:
...Pfizer and BioNTech started enrolling participants in a trial of their mRNA flu shot last September....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...It was made by US pharmaceutical giant Pfizer and Germany's BioNTech....
...Gregory M....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Dr Gregory Glenn, president of research and development at Novavax, admitted the company had been “in bad shape”, but said he believed the Covid-19 vaccine would validate much of the company’s other work...
...These included acquisitions such as Ewos, a Norwegian salmon feed company, and Diamond V, a manufacturer of yeast culture products to aid animal health....
...To give you a sense of how desperate companies are to secure new assets you just need to remember how Sanofi started a bidding war for Medivation, only to lose out to Pfizer in August 2016, and how it later...
...Merck, the drug manufacturer, dropped 2.8 per cent to $55.89, Pfizer fell 1.5 per cent to $34.22 and Johnson & Johnson lost 1 per cent to $115.48....
...Gregory Wasson, Walgreens chief executive, told the Financial Times an inversion would likely have faced “intense and maybe prolonged” scrutiny from US tax authorities....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Gregory Kalbaugh, director and counsel at the business council, says: “Most companies would like to invest in India.”...
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition